DFTX
HOLD / NEUTRALMeanRevComposite
51.20
Technical
100.00
Fundamental
34.90
Rank
—
Price
48.45
Hurst
0.15
As of
Jul 10, 2026
Daily
Definium Therapeutics, Inc.
HealthcareBiotechnologyDefinium Therapeutics is a biopharmaceutical firm focused on developing treatments for neurological and psychiatric conditions. The company's primary experimental drugs include DT120, currently in late-stage testing for anxiety and depression disorders, and DT402, an investigational compound in earlier trials for autism spectrum disorder. Headquartered in New York, the company was previously known as Mind Medicine before rebranding in early 2026.
Market cap
$4.9B
P/E (trailing)
—
P/E (forward)
-18.66
PEG ratio
—
Dividend yield
0.00%
Beta
2.19
52w range
10.47 – 49.70
Return on equity
-64.09%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 36.22 (+170.5%) · range 10.68–48.45
Cycle position
51/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 19 · NOT READY · exit proximity 0
Conviction
17/ 100 · maturity 0%
Buildup.332
EMA entry setup.4219
Fundamentals.2535
Volume profile
POC
44.54
Price vs POC
-18.7%
Overhead supply
70%
Runway
+4.5%
Value area 35.73–47.27 · 70% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -1.98% | -1.98% | mature |
| 40d | -19.08% | -1.89% | mature |